益盛药业：上半年归母净利润1876.38万元

Core Viewpoint - Yisheng Pharmaceutical reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 328 million yuan, a year-on-year decrease of 5.75% [1] - The net profit attributable to shareholders was 18.76 million yuan, down 43.71% compared to the previous year [1] - Basic earnings per share were 0.0567 yuan, reflecting a decline of 43.69% year-on-year [1] Dividend Policy - The company announced plans not to distribute cash dividends, issue bonus shares, or increase capital through reserves [1]